Bomedemstat

Bomedemstat
Clinical data
Other names	IMG-7289
Identifiers
	IUPAC name N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide;
CAS Number	1990504-34-1;
PubChem CID	122460381;
DrugBank	DB15126;
ChemSpider	75531282;
UNII	Y2T4ALDEAT;
ChEMBL	ChEMBL4297289;
Chemical and physical data
Formula	C28H34FN7O2
Molar mass	519.625 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCN(CC1)C(=O)[C@H](CCCN[C@@H]2C[C@H]2C3=CC=C(C=C3)F)NC(=O)C4=CC=C(C=C4)N5C=CN=N5;
	InChI InChI=1S/C28H34FN7O2/c1-34-15-17-35(18-16-34)28(38)25(3-2-12-30-26-19-24(26)20-4-8-22(29)9-5-20)32-27(37)21-6-10-23(11-7-21)36-14-13-31-33-36/h4-11,13-14,24-26,30H,2-3,12,15-19H2,1H3,(H,32,37)/t24-,25-,26+/m0/s1; Key:KQKBMHGOHXOHTD-KKUQBAQOSA-N;

Bomedmestat (USAN; IUPAC name N-[(2S)-5-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(triazol-1-yl)benzamide) is an investigational drug under development by Imago BioSciences for the treatment of myeloproliferative neoplasms including essential thrombocythemia, polycythemia vera, myelofibrosis^[1] and small-cell lung cancer.^[2]

^ "Bomedemstat". PubChem. U.S. National Library of Medicine.
^ "A Phase I/II Study of Bomedemstat Combined With Maintenance Immunotherapy for Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC)". clinicaltrials.gov. 2 May 2024. Retrieved 12 May 2024.

[1] "Bomedemstat". PubChem. U.S. National Library of Medicine.

[2] "A Phase I/II Study of Bomedemstat Combined With Maintenance Immunotherapy for Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC)". clinicaltrials.gov. 2 May 2024. Retrieved 12 May 2024.

[1]

[2]